AstraZeneca Shareholders Revolt Again Over Executive Pay

AstraZeneca has suffered another shareholder revolt over executive pay, with two-fifths opposing a £13m package for its chief executive. Nearly 39% of investors voted against the pharmaceutical group’s 2016 remuneration report at its annual meeting in London, similar to the rebellion it faced three years ago . Support for the new pay policy was much stronger, with 96% of investors backing it...
Login to comment.